Home

Relevant Information

Information about the areas in which we work

PAIN

In ESTEVE we are committed on doing research as closely as possible to patient needs. The treatment of pain constitutes one of our main priorities.

+ Information external links

19%

Chronic pain of moderate to severe intensity occurs in 19% of adult Europeans, seriously affecting the quality of their social and working lives, and 50% of them endure inadequate pain relief for at least two years. (Breivik H, et al. 2005).

It is estimated that 9% of the U.S. adult population suffer from moderate to severe non-cancer related chronic pain. (American Pain Society).

Chronic pain is characterized by high levels of unmet medical needs. Current treatments do not provide satisfactory levels of pain relief in the majority of patients and are associated with high levels of not desirable events.

Chronic pain is a major public health problem with a profound impact on the quality of life of the patient (sleeping disorders, reduced mobility or depression) affecting work productivity and with a high impact in the cost of healthcare.

The treatment of pain is one of our main priorities.
See video to learn more about our projects in pain.

American Academy of Pain Management
http://www.aapainmanage.org

American Pain Society
http://www.ampainsoc.org

International Association for the Study of Pain
http://www.iasp-pain.org

American Chronic Pain Association
http://www.theacpa.org

American Pain Foundation
http://www.painfoundation.org

Beth Israel Medical Center
(Department of Pain Medicine & Palliative Care)
http://www.stoppain.org

World Institute of Pain
http://worldinstitueofpain.org

The European Society of Regional Anaesthesia & Pain Therapy
http://www.esraeurope.org

The NIH pain consortium
http://painconsortium.nih.gov

WHO's pain ladder (World Health Organization)
http://www.who.int/cancer/palliative/painladder/en

The European Federation of the IASP
http://efic.org

Pain Management Resource by Dannemiller
http://pain.com

Purdue Pharma L.P. established Partners Against Pain, an alliance of patients, caregivers, and healthcare providers dedicated to pain management education and advocacy.
www.partnersagainstpain.com/

Pain Alliance Europe
www.pae-eu.eu

HIV/AIDS

ESTEVE believes in a socially responsible, collaborative approach when it comes to fighting against a disease of epidemic proportion like HIV.

+ Information external links

HIV/AIDS is a leading cause of death in the developing world and remains one of the world's most significant public health challenges.

33.3

33.3 million people live with HIV/AIDS of whom more than 30 million were living in low- and middle-income countries.

Standard antiretroviral therapy suppresses the HIV virus and stops the progression of HIV disease, enabling HIV-positive patients to live longer and healthier lives.

14.6

At least 14.6 million people were in need of antiretroviral therapy in 2009. As of the end of 2009, only 5.25 million people had access to antiretroviral therapy in low- and middle-income countries. (Source: World Health Organization)

Our contribution to help develop an effective HIV vaccine as a part of the HIVACAT project.
See video to learn more about our collaborative approach in HIV.

World Health Organization (HIV/AIDS)
http://www.who.int/hiv/en/

AIDS Vaccine Research Project
http://www.hivacat.org/en

United Nations Programme on HIV/AIDS
http://www.unaids.org/en/

UNICEF HIV/AIDS and children
http://www.unicef.org/aids/index.html

AIDS Program from US Government
http://aids.gov/

ArtAids emplea el arte en la lucha contra el SIDA
http://www.artaids.com

International AIDS Economics Network
http://www.iaen.org/

Podcast

AIDS/HIV Podcasts and Interviews
http://www.webicina.com/hiv-and-aids/aids-hiv-podcasts-and-intrerviews/

RARE DISEASES

ESTEVE devotes significant research efforts in diseases for which doesn’t exist a cure.

+ Information external links

Rare diseases are often disorders with inadequate or no effective treatment available and frequently involve chronic illness, disability, and premature death. (source: public health portal of the European Union- Rare Diseases).

80%

80% of rare diseases are genetic, and thus are present throughout the person's entire life. (source: The Therapeutics for Rare and Neglected Diseases program from NIH).

7,000

A rare disease occurs in less than 200,000 individuals in the United States, or less than 5 per 10,000 individuals in the European Union. However the number of sufferers may still be high, as there are some 7,000 known rare diseases.

Diagnosis of many rare diseases are lengthy and time consuming and is only initiated once the symptoms have begun to appear like the Sanfilippo Syndrome, a lysosomal storage disease caused by the loss of the activity of the enzyme sulfamidase.

Sanfilippo Syndrome is a devastating disease that leads to progressive and significant deterioration in mental status of children who rarely live beyond their twenties.

Gene therapy approach to treat Sanfilippo Syndrome, a devastating rare disease affecting children.
See video to learn more about our research efforts in rare diseases.

Rare Disorders

US Organization for Rare Disorders
http://www.rarediseases.org/

The voice of rare disease patients in Europe
http://www.eurordis.org

The National UK Alliance for people with rare diseases and all who support them
http://www.raredisease.org.uk/

The Public Health Portal of the European Union
http://ec.europa.eu/health-eu/health_problems/rare_diseases/index_en.htm

US Office of Rare Diseases Research
http://rarediseases.info.nih.gov/

Sanfilippo

UK Society Society for Mucopolysaccharide Diseases
http://www.mpssociety.co.uk/index.php?page=sanfilippo-disease

Medscape: Genetics of Mucopolysaccharidosis Type III
http://emedicine.medscape.com/article/948540-overview

Pubmed: Sanfilippo syndrome
http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002190/

Information about Sanfilippo Syndrome and the families who deal with it
http://www.curesf.org/

Gene Therapy